Cargando…
Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
TP53 mutations are associated with poor prognosis in the vast majority of cancers. In this study, we present a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient carrying a rare TP53 c.C275T mutation. This extremely rare mutation affects an amino acid residue located between the TAD domai...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928200/ https://www.ncbi.nlm.nih.gov/pubmed/36798689 http://dx.doi.org/10.3389/fonc.2022.1018250 |
_version_ | 1784888602814054400 |
---|---|
author | Wang, Runan Wang, Wenliang Liu, Xuan Wang, Huan Zhang, Bin Li, Shuang Zhang, Haining Yang, Jiawei Zhao, Jishun He, Qiuying Zhang, Jihong Liu, Danping Hao, Liangchun |
author_facet | Wang, Runan Wang, Wenliang Liu, Xuan Wang, Huan Zhang, Bin Li, Shuang Zhang, Haining Yang, Jiawei Zhao, Jishun He, Qiuying Zhang, Jihong Liu, Danping Hao, Liangchun |
author_sort | Wang, Runan |
collection | PubMed |
description | TP53 mutations are associated with poor prognosis in the vast majority of cancers. In this study, we present a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient carrying a rare TP53 c.C275T mutation. This extremely rare mutation affects an amino acid residue located between the TAD domain and the DNA-binding domain of p53. The patient was resistant to most conventional chemotherapy regimens and remained minimal residual disease (MRD)-positive after five rounds of such regimens. We tested the sensitivity of the patient’s leukemic cells to 21 anti-cancer drugs by performing in vitro drug sensitivity assays. The results showed that bortezomib had a very strong killing effect on the patient’s leukemic cells. Therefore, we subsequently treated the patient with bortezomib combined with vindesine, cytarabine, and fludarabine. After one course of treatment, the patient became MRD-negative, and there was no recurrence during a 9-month follow-up. In conclusion, our report suggests that the TP53 c.C275T mutation is associated with poor prognosis in B-ALL. Fortunately, bortezomib combined with chemotherapy could achieve a better therapeutic effect than conventional regimens in this type of ALL. |
format | Online Article Text |
id | pubmed-9928200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99282002023-02-15 Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report Wang, Runan Wang, Wenliang Liu, Xuan Wang, Huan Zhang, Bin Li, Shuang Zhang, Haining Yang, Jiawei Zhao, Jishun He, Qiuying Zhang, Jihong Liu, Danping Hao, Liangchun Front Oncol Oncology TP53 mutations are associated with poor prognosis in the vast majority of cancers. In this study, we present a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient carrying a rare TP53 c.C275T mutation. This extremely rare mutation affects an amino acid residue located between the TAD domain and the DNA-binding domain of p53. The patient was resistant to most conventional chemotherapy regimens and remained minimal residual disease (MRD)-positive after five rounds of such regimens. We tested the sensitivity of the patient’s leukemic cells to 21 anti-cancer drugs by performing in vitro drug sensitivity assays. The results showed that bortezomib had a very strong killing effect on the patient’s leukemic cells. Therefore, we subsequently treated the patient with bortezomib combined with vindesine, cytarabine, and fludarabine. After one course of treatment, the patient became MRD-negative, and there was no recurrence during a 9-month follow-up. In conclusion, our report suggests that the TP53 c.C275T mutation is associated with poor prognosis in B-ALL. Fortunately, bortezomib combined with chemotherapy could achieve a better therapeutic effect than conventional regimens in this type of ALL. Frontiers Media S.A. 2023-01-31 /pmc/articles/PMC9928200/ /pubmed/36798689 http://dx.doi.org/10.3389/fonc.2022.1018250 Text en Copyright © 2023 Wang, Wang, Liu, Wang, Zhang, Li, Zhang, Yang, Zhao, He, Zhang, Liu and Hao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Runan Wang, Wenliang Liu, Xuan Wang, Huan Zhang, Bin Li, Shuang Zhang, Haining Yang, Jiawei Zhao, Jishun He, Qiuying Zhang, Jihong Liu, Danping Hao, Liangchun Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report |
title | Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report |
title_full | Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report |
title_fullStr | Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report |
title_full_unstemmed | Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report |
title_short | Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report |
title_sort | treatment for a b-cell acute lymphoblastic leukemia patient carrying a rare tp53 c.c275t mutation: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928200/ https://www.ncbi.nlm.nih.gov/pubmed/36798689 http://dx.doi.org/10.3389/fonc.2022.1018250 |
work_keys_str_mv | AT wangrunan treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT wangwenliang treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT liuxuan treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT wanghuan treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT zhangbin treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT lishuang treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT zhanghaining treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT yangjiawei treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT zhaojishun treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT heqiuying treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT zhangjihong treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT liudanping treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport AT haoliangchun treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport |